Summit buys microkeratome from EyeTech Vision
This article was originally published in Clinica
Ophthalmic laser company Summit Technology has bought the Krumeich-Barraquer microkeratome from EyeTech Vision, which is based in Liechtenstein and the US, for an undisclosed sum. Summit will begin selling the high precision, corneal surgical device to international customers immediately. The Waltham, Massachusetts-based company will commence sales in the US upon receipt of FDA 510(k) clearance.
You may also be interested in...
Private Company Edition: While venture capital invested in the industry dropped in 2019, the number of deals rose as investors funded more early-stage VC rounds. Money continues flowing to large deals as well, including $105m for ALX Oncology and $98m for CANbridge.
Roughly 18.5% of patients who received reinterventions to fix mesh implants for pelvic organ prolapse (POP) repair experienced complications they will likely endure for the rest of their lives, and they also face a 2.5% higher rate of further surgeries than non-mesh patients, says a recent 54,194-woman study detailed in Obstetrics & Gynecology. The study authors lay out a case that the US FDA should have forced removal of mesh from the market sooner.